Pfizer (PFE) Expected to Announce Earnings on Tuesday

Pfizer (NYSE:PFE) is anticipated to announce its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Pfizer to announce earnings of $0.7280 per share and revenue of $15.86 billion for the quarter. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 3, 2026 at 10:00 AM ET.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter last year, the business earned $0.78 earnings per share. Pfizer’s revenue was up 2.6% compared to the same quarter last year. On average, analysts expect Pfizer to post $2.94 EPS for the current fiscal year and $2.95 EPS for the next fiscal year.

Pfizer Price Performance

Shares of NYSE:PFE opened at $29.80 on Tuesday. The firm’s 50 day moving average is $28.30 and its two-hundred day moving average is $26.67. The firm has a market capitalization of $169.82 billion, a P/E ratio of 39.20, a PEG ratio of 2.04 and a beta of 0.32. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. Pfizer has a 52 week low of $23.62 and a 52 week high of $30.44.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 5.8%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio is 226.32%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported that its Phase 3 MagnetisMM-32 trial of ELREXFIO in relapsed or refractory multiple myeloma met its primary progression-free-survival endpoint at an interim analysis and outperformed standard treatment regimens. The result strengthens the drug’s potential as a growth driver, though full data and regulatory steps remain ahead. Pfizer ELREXFIO Phase 3 study results
• Positive Sentiment: The FDA expanded approval for Pfizer’s TALZENNA plus XTANDI combination into an earlier treatment setting for men with metastatic hormone-sensitive prostate cancer and HRR gene mutations, including BRCA and non-BRCA mutations. The broader label increases the drugs’ addressable patient population and commercial opportunity. Pfizer TALZENNA and XTANDI FDA approval
• Neutral Sentiment: Pfizer presented Phase 2 results across serotypes for its 25-valent pneumococcal vaccine candidate, 25vPnC. The update provides additional pipeline information, but the eventual stock impact depends on detailed efficacy, safety, and regulatory outcomes. Pfizer 25vPnC Phase 2 results
• Neutral Sentiment: Pfizer appeared relatively resilient as broader healthcare stocks weakened, suggesting limited company-specific pressure from the sector’s late-session softness. Healthcare sector update
• Negative Sentiment: After a strong 2026 advance, valuation-focused coverage argues that Pfizer’s shares may be above fair value, with estimates indicating limited or negative upside from current levels. This raises the risk of profit-taking unless earnings and pipeline growth accelerate. Pfizer valuation and November 3 outlook

Analysts Set New Price Targets

Several analysts have weighed in on PFE shares. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, October 13th. JPMorgan Chase & Co. increased their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 9th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. BMO Capital Markets lowered their price target on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Finally, Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Five investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $28.72.

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.